Posted by Michael Wonder on 30 Nov 2022
Ripretinib for the treatment of patients with an advanced gastro-intestinal stromal tumour after three or more therapies
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ripretinib in the NHS in England.
Ripretinib is not recommended for the treatment of adults with an advanced gastro-intestinal stromal tumour after the use of three or more tyrosine kinase inhibitors, including imatinib mesylate.
